Effect of albumin administration on outcomes in hypoalbuminemic patients hospitalized with community-acquired pneumonia (ALBUCAP): a prospective, randomized, phase III clinical controlled trial—a trial protocol

• Published in: Current controlled trials in cardiovascular medicine 2020-08, Vol.21 (1), p.727-727, Article 727
• Main Authors: Rombauts, Alexander, Abelenda-Alonso, Gabriela, Simonetti, Antonella Francesca, Verdejo, Guillermo, Meije, Yolanda, Ortega, Lucia, Clemente, Mercedes, Niubó, Jordi, Ruiz, Yolanda, Gudiol, Carlota, Tebé, Cristian, Videla, Sebastian, Carratalà, Jordi
• Format: Article
• Language: English
• Subjects: Albumin; Antibiotics; Antigens; Ascites; Bacterial infections; Care and treatment; Clinical trials; Community-acquired infections; Community-acquired pneumonia; Health aspects; Hospitalization; Hypoxia; Inflammation; Liver cirrhosis; Mortality; Nosocomial infections; Patient outcomes; Patients; Pneumonia; Protein deficiency; Randomized controlled trial; Sepsis; Study Protocol; Testing
• ISSN: 1745-6215; 1745-6215
• DOI: 10.1186/s13063-020-04627-1

Background Community-acquired pneumonia (CAP) remains a leading cause of death worldwide, and hypoalbuminemia is associated with worse outcomes. However, it remains uncertain whether albumin administration could have any beneficial effects. We aim to assess whether the administration of albumin in hypoalbuminemic patients with CAP increases the proportion of clinically stable patients at day 5 compared with the standard of care alone. Methods This is a trial protocol for a superiority, non-blinded, multicenter, randomized, phase 3, interventional controlled clinical trial. The primary endpoint will be the proportion of clinical stable patients at day 5 (intention to treat), defined as those with stable vital signs for at least 24 h. The secondary endpoints will be time to clinical stability, duration of intravenous and total antibiotic treatment, length of hospital stay, intensive care unit admission, duration of mechanical ventilation and vasopressor treatment, adverse events, readmission within 30 days, and all-cause mortality. The trial has been approved by the Spanish Medicines and Healthcare Products Regulatory Agency. The investigators commit to publish the data in peer-reviewed journals within a year of the study completion date. Subjects will be recruited from three Spanish hospitals over a planned enrolment period of 2 years. A follow-up visit will be performed 1 month after discharge. We have estimated the need for a sample size of 360 patients at a two-sided 5% alpha-level with a power of 80% based on intention to treat. Eligible participants must be hospitalized, hypoalbuminemic ([less than or equai to] 30 g/L), non-immunosuppressed, adults, and diagnosed with CAP. They will be randomly assigned (1:1) to receive standard care plus albumin (20 g in 100 mL) every 12 h for 4 days or standard care alone. Discussion If this randomized trial confirms the hypothesis, it should lead to a change in current clinical practice for the management of hypoalbuminemic patients with CAP. Trial registration European Clinical Trials Database (EudraCT) 2018-003117-18. Registered on 12 April 2019. ClinicalTrials.gov NCT04071041. Registered on 27 August 2019 Keywords: Community-acquired pneumonia, Albumin, Inflammation, Randomized controlled trial